Assessing ChatGPT vs. evidence-based online responses for polycystic ovary syndrome self-management and education: an international cross-sectional blinded survey of healthcare professionals - Summary - MDSpire
Advertisement
Assessing ChatGPT vs. evidence-based online responses for polycystic ovary syndrome self-management and education: an international cross-sectional blinded survey of healthcare professionals
To assess the reliability of ChatGPT-generated responses to frequently asked questions about PCOS compared to evidence-based recommendations, focusing on accuracy and clarity.
Key Findings:
ChatGPT responses were rated significantly higher than evidence-based responses for 11 out of 12 questions, indicating a preference for AI-generated content.
Moderate to large effect sizes were observed (rrb = −0.46 to −1.00; all p-values <0.05), suggesting substantial differences in ratings.
The average rating difference was 0.824 units in favor of ChatGPT, highlighting its perceived effectiveness.
Scoring agreement varied from poor to fair, with seven questions showing fair agreement (κ = 0.24–0.37, p < 0.05), indicating variability in evaluations.
No significant differences in readability between ChatGPT and evidence-based responses were found, but simplification of responses improved clarity.
Interpretation:
ChatGPT shows potential as a complementary tool for patient self-education in PCOS, enhancing engagement and simplifying complex medical language, which could improve patient understanding.
Limitations:
Sample size limited to 43 healthcare professionals, which may affect the generalizability of the findings.
Scoring agreement varied, indicating inconsistent evaluations among participants.
Further research is needed to validate clinical applicability and integration of AI tools in diverse healthcare settings.
Conclusion:
ChatGPT may serve as a valuable resource for PCOS education, but further studies are necessary to optimize its use in clinical settings and explore its impact on patient outcomes.
In a target-trial emulation of more than 600,000 veterans, GLP-1 RA initiators saw fewer new substance use disorders—and patients with existing SUDs had fewer overdoses, hospitalizations, and deaths.
